Aiming to build a bridge between academics and industry, Protheragen, a company founded in Ronkonkoma, New York, 2009, announces to offer license opportunities for drug R&D companies. Protheragen is previously known for three businesses, including: intermediary service, project incubation, and equity investment.

For pharmaceutical companies, the seeking of high-quality novel drug research and development programs is not always easy. “Fully aware of how hard it is to successfully develop a new drug, we decide to provide free access to licensing opportunities concerning drug development programs,” says the Marketing Chief of Protheragen. “We aspire to play a role in transforming the scientific innovations into medications, helping patients with the most challenging diseases.”

The majority projects that are ready to be licensed are focused on oncology, and many of them are at preclinical stage with great therapeutic and market potential. In terms of different treatment methods, the programs can be categorized as the follows:

Antibody Therapy
There are more than ten projects in this type. Most are in preclinical stage and have potentials to treat cancer.

Recombinant Protein Therapy
There are four projects in this category with potentials to treat neurological diseases, type 2 diabetes, acute myeloid leukemia, and surgical bleeding and trauma. Among them, the surgical bleeding pipeline has reached Phase II clinical trials.Ⅱ

Small Molecules
There are ten projects in this category with diversified implications such as cancer, pain, hepatitis B, nonalcoholic steatohepatitis, Alzheimer’s disease, psoriasis, (+)ssRNA virus infections, etc. Among them, two have entered Phase II clinical trials.Ⅱ

In addition to the above-mentioned projects, Protheragen also offers licensing opportunities for Oncolytic Virotherapy, Cell Therapy, and RNA Therapy. Please visit https://www.protheragen.com/available-projects.html to learn more.

Author's Bio: 

During the past decade and more, Protheragen has grown to be a trust-worthy intermediary service provider. In order to bring out more for our clients, it has shifted to strategies that require constantly seeking of high-quality novel drug research and development programs, which are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, the company welcomes partnerships in areas of equity investment, intermediary service and project incubation.